Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Nanomedicine-mediated induction of immunogenic cell death and prevention of PD-L1 overexpression for enhanced hepatocellular carcinoma therapy

Fig. 3

NPDOX/siPD-L1 induced ICD of H22 cells and inhibited overexpression of PD-L1. a, b FITC was used to label siRNA and DOX signal was used to label DOX. Flow cytometry was used to analyze internalization of NPDOX/siPD-L1 internalization. d CRT positive cells were analyzed using Flow cytometry. e, f Released HMGB1 and ATP were determined after the H22 cells were treated with NPDOX/siPD-L1. g The mRNA and protein levels of PD-L1 were determined using RT-qPCR and western blot, respectively. As shown in the h, treated H22-OVA cell were co-incubated with CD8+ T cells, and the apoptosis of H22 cells was determined. i Annexin V/PI double staining were applied and flow cytometry was used to determine cell apoptosis. Data were represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. All the experiments were repeated three times with similar results

Back to article page